Emergent Biosolutions Inc.

EBS Healthcare Drug Manufacturers Specialty & Generic

Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.

6.38 0.80 −11.14%
Market cap
$368.1M
P/E
0.0×
Fwd P/E
−26.5×
Dividend yield
—
F-score
6/9
Altman Z
1.63
Beneish M
−3.56
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

13.92% 10.46% (1.60%) (40.29%)
Piotroski F-Score
5 6 5 5
ROA
5.17% 3.88% (0.63%) (13.95%)
ROIC
7.43% 7.06% 4.06% (5.27%)
Return on Tangible Assets
8.82% 7.15% (1.25%) (24.51%)
Average Days of Receivables
69.17 41.37 65.58 90.04
Free Cash Flow per Share
0.75 3.64 2.61 1.67
Free Cash Flow
39.90 195.00 135.50 86.10
Capital Expenditures
26.90 24.40 (12.50) (11.60)
Other line items
Cash ROIC
2.67% 14.96% 10.77% 8.09%
Accounts Receivable Turnover
5.83 6.22 4.16 5.71
Accounts Payable Turnover
5.15 5.60 6.35 5.97
Inventory Turnover
1.06 1.00 0.97 1.06
Average Days of Payables
58.31 62.21 46.55 53.91
Days of Inventory on Hand
361.95 384.25 386.10 326.02
Tax Rate
(0.28) (0.36) (3.46) 0.21
Research and Development Expense of Revenue
6.36% 7.16% 7.18% 5.88%
Selling, General and Administrative Expense of Revenue
24.82% 25.05% 26.64% 23.53%
Share Based Compensation of Revenue
1.93% 2.18% 2.45% 2.45%
Interest Coverage
2.00 1.69 1.09 (1.30)
Operating CF/Net income
0.17 3.24 (17.21) (0.55)
Depreciation/Fixed assets
0.51 0.51 0.52 0.58
Capex/Depreciation
0.25 0.23 (0.12) (0.11)
Revenue per Share
14.83 13.89 13.04 14.93
Operating CF per Share
0.24 3.19 2.85 1.89
Capex per Share
0.51 0.46 (0.24) (0.22)
Capex to Sales
(0.03) (0.03) 0.02 0.02

Fold the line items

Columns are period end dates